Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash & Equivalents (2016 - 2025)

Lisata Therapeutics' Cash & Equivalents history spans 13 years, with the latest figure at $16.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 1.56% year-over-year to $16.0 million; the TTM value through Dec 2025 reached $16.0 million, down 1.56%, while the annual FY2025 figure was $16.0 million, 1.56% down from the prior year.
  • Cash & Equivalents reached $16.0 million in Q4 2025 per LSTA's latest filing, down from $19.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $32.4 million in Q3 2023 to a low of $12.1 million in Q2 2025.
  • Average Cash & Equivalents over 3 years is $20.3 million, with a median of $19.3 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: increased 0.72% in 2024, then plummeted 49.22% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $22.6 million in 2023, then fell by 28.26% to $16.2 million in 2024, then dropped by 1.56% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Cash & Equivalents are $16.0 million (Q4 2025), $19.0 million (Q3 2025), and $12.1 million (Q2 2025).